Elicio Therapeutics Inc
ELTX8.195USD
+0.255+3.21%
Market hours （ET）Quotes delayed by 15 min
141.43MMarket Cap
LossP/E TTM
More Details of Elicio Therapeutics Inc Company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Elicio Therapeutics Inc Info
Ticker SymbolELTX
Company nameElicio Therapeutics Inc
IPO dateFeb 05, 2021
CEOConnelly (Robert)
Number of employees32
Security typeOrdinary Share
Fiscal year-endFeb 05
Address451 D Street, 5Th Floor
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02459
Phone18572090050
Websitehttps://elicio.com/
Ticker SymbolELTX
IPO dateFeb 05, 2021
CEOConnelly (Robert)
Company Executives of Elicio Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 23
Updated: Sun, Nov 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
Other
58.42%
Shareholders
Shareholders
Proportion
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
Other
58.42%
Shareholder Types
Shareholders
Proportion
Corporation
32.50%
Hedge Fund
4.86%
Investment Advisor
4.52%
Holding Company
2.75%
Investment Advisor/Hedge Fund
2.25%
Individual Investor
1.51%
Research Firm
0.18%
Other
51.42%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
58
2.05M
11.00%
--
2025Q3
59
2.05M
11.96%
+477.65K
2025Q2
52
1.58M
11.53%
-116.12K
2025Q1
59
1.67M
8.91%
+250.74K
2024Q4
54
504.27K
8.35%
-37.38K
2024Q3
58
541.64K
9.80%
-115.54K
2024Q2
70
657.30K
8.80%
+242.22K
2024Q1
96
415.08K
8.40%
-443.93K
2023Q4
102
540.87K
10.06%
+911.00
2023Q3
115
547.56K
11.25%
+45.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GKCC, LLC
5.42M
33.15%
--
--
Jun 03, 2025
Knoll Capital Management, LLC
630.91K
3.86%
--
--
Jun 30, 2025
Clal Biotechnology Industries Ltd
481.73K
2.95%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
454.62K
2.78%
+132.93K
+41.32%
Jun 30, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.24%
+268.56K
+45.69%
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.04%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
120.83K
0.74%
+43.36K
+55.98%
Jun 30, 2025
Susquehanna International Group, LLP
17.02K
0.1%
-14.34K
-45.72%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Date
Type
Ratio
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Elicio Therapeutics Inc?
The top five shareholders of Elicio Therapeutics Inc are:
GKCC, LLC holds 5.42M shares, accounting for 33.15% of the total shares.
Knoll Capital Management, LLC holds 630.91K shares, accounting for 3.86% of the total shares.
Clal Biotechnology Industries Ltd holds 481.73K shares, accounting for 2.95% of the total shares.
The Vanguard Group, Inc. holds 454.62K shares, accounting for 2.78% of the total shares.
Actyus Private Equity SGIIC, S.A. holds 856.38K shares, accounting for 5.24% of the total shares.
GKCC, LLC holds 5.42M shares, accounting for 33.15% of the total shares.
Knoll Capital Management, LLC holds 630.91K shares, accounting for 3.86% of the total shares.
Clal Biotechnology Industries Ltd holds 481.73K shares, accounting for 2.95% of the total shares.
The Vanguard Group, Inc. holds 454.62K shares, accounting for 2.78% of the total shares.
Actyus Private Equity SGIIC, S.A. holds 856.38K shares, accounting for 5.24% of the total shares.
What are the top three shareholder types of Elicio Therapeutics Inc?
The top three shareholder types of Elicio Therapeutics Inc are:
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd
How many institutions hold shares of Elicio Therapeutics Inc (ELTX)?
As of 2025Q4, 58 institutions hold shares of Elicio Therapeutics Inc, with a combined market value of approximately 2.05M, accounting for 11.00% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.96%.
What is the biggest source of revenue for Elicio Therapeutics Inc?
In --, the -- business generated the highest revenue for Elicio Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
